Examining the interplay between cerebrovascular compromise and AD in the development of therapies is complicated by long prodromal phases of both conditions, necessitating preclinical studies. Four-month-old TgAD-F344 rats, which by six months of age present amyloid deposits and hyperphosphorylated tau, were treated with a nitric oxide synthase inhibitor L-NAME for one month to induce transient hypertension. Human umbilical cord perivascular cells were then given in combination with scyllo-inositol, an inhibitor of Abeta peptide oligomerization and fibrillization to elicit cerebrovascular repair and clear amyloid. Following L-NAME, non-transgenic rats showed transient cerebrovascular changes, whereas TgAD-F344 animals exhibited sustained increase in cerebrovascular reactivity. The latter effect was ameliorated by the treatment.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords